Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Claims New Drugs, Pipeline Will Fuel Growth, Not M&A

Executive Summary

Novartis sees itself engaging in only modest M&A activity to avoid over-paying for targets - and will rely on newly launched drugs and promising external targets to grow sales.

You may also be interested in...



First In MS: Fingolimod Nears Market For Relapsing MS In Children, Adolescents

Per initial data from Novartis's PARADIGMS study in adolescents and children, Gilenya is the first therapy shown to reduce MS relapses in younger patients in a controlled late-stage clinical study, and Novartis says it will prepare marketing submissions for the additional indication after fully analyzing the data.

Novartis' Rydapt: Two Indications, Two Prices

Rydapt was approved by the US FDA for the one-third of patients with acute myeloid leukemia who test positive for a FLT3 mutation, which is associated with a poorer prognosis, and for advanced systemic mastocytosis.

Heartache For Novartis As Serelaxin Failure Ups Pressure On Entresto

Novartis's latest Phase III study of serelaxin has failed, deleting a significant chunk of forecasted revenue that analysts had attributed to the heart failure drug candidate.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel